Pharmacy practice research priorities during the COVID-19 pandemic: Recommendations of a panel of experts convened by FIP Pharmacy Practice Research Special Interest Group.

Dawoud, D; Chen, AMH; Rossing, CV; Garcia-Cardenas, V; Law, AV; Aslani, P; Bates, I; Babar, Z-U-D; Desselle, S

Pharmacy practice research priorities during the COVID-19 pandemic: Recommendations of a panel of experts convened by FIP Pharmacy Practice Research Special Interest Group.

Dawoud, D Chen, AMH Rossing, CV Garcia-Cardenas, V Law, AV Aslani, P Bates, I Babar, Z-U-D Desselle, S

Permalink

Publisher:: ELSEVIER SCIENCE INC
Publication Type:: Journal Article
Citation:: Research in social & administrative pharmacy : RSAP, 2021, 17, (1), pp. 1903-1907
Issue Date:: 2021-01-01

Closed Access

	Filename	Description	Size
	Pharmacy practice research priorities during the COVID-19 pandemic Recommendations of a panel of experts convened by FIP Pha.pdf		405.45 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Dawoud, D
dc.contributor.author	Chen, AMH
dc.contributor.author	Rossing, CV
dc.contributor.author	Garcia-Cardenas, V
dc.contributor.author	Law, AV
dc.contributor.author	Aslani, P
dc.contributor.author	Bates, I
dc.contributor.author	Babar, Z-U-D
dc.contributor.author	Desselle, S
dc.date.accessioned	2022-01-06T03:38:06Z
dc.date.available	2020-08-24
dc.date.available	2022-01-06T03:38:06Z
dc.date.issued	2021-01-01
dc.identifier.citation	Research in social & administrative pharmacy : RSAP, 2021, 17, (1), pp. 1903-1907
dc.identifier.issn	1551-7411
dc.identifier.issn	1934-8150
dc.identifier.uri	http://hdl.handle.net/10453/152735
dc.description.abstract	Across the globe, pharmacists on the frontline continue to fight COVID-19 and its continuously evolving physical, mental, and economic consequences armed by their knowledge, professionalism, and dedication. Their need for credible scientific evidence to inform their practice has never been more urgent. Despite the exponentially increasing number of publications since the start of the pandemic, questions remain unanswered, and more are created, than have been resolved by the increasing number of publications. A panel of leading journal editors was convened by the International Pharmaceutical Federation (FIP) Pharmacy Practice Research Special Interest Group to discuss the current status of COVID-19 related research, provide their recommendations, and identify focal points for pharmacy practice, social pharmacy, and education research moving forward. Key priorities identified spanned a wide range of topics, reflecting the need for good quality research to inform practice and education. The panel insisted that a foundation in theory and use of rigorous methods should continue forming the basis of inquiry and its resultant papers, regardless of topic area. From assessing the clinical and cost effectiveness of COVID-19 therapies and vaccines to assessing different models of pharmaceutical services and education delivery, these priorities will ensure that our practice is informed by the best quality scientific evidence at this very challenging time.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	ELSEVIER SCIENCE INC
dc.relation.ispartof	Research in social & administrative pharmacy : RSAP
dc.relation.isbasedon	10.1016/j.sapharm.2020.08.020
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences, 1117 Public Health and Health Services
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.mesh	COVID-19
dc.subject.mesh	Humans
dc.subject.mesh	Pharmaceutical Services
dc.subject.mesh	Pharmacists
dc.subject.mesh	Pharmacy Research
dc.subject.mesh	Professional Role
dc.subject.mesh	Professionalism
dc.subject.mesh	Humans
dc.subject.mesh	Professional Role
dc.subject.mesh	Pharmacists
dc.subject.mesh	Pharmaceutical Services
dc.subject.mesh	Professionalism
dc.subject.mesh	Pharmacy Research
dc.subject.mesh	COVID-19
dc.title	Pharmacy practice research priorities during the COVID-19 pandemic: Recommendations of a panel of experts convened by FIP Pharmacy Practice Research Special Interest Group.
dc.type	Journal Article
utslib.citation.volume	17
utslib.location.activity	United States
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
pubs.consider-herdc	true
dc.date.updated	2022-01-06T03:38:03Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	17
utslib.citation.issue	1

Abstract:

Across the globe, pharmacists on the frontline continue to fight COVID-19 and its continuously evolving physical, mental, and economic consequences armed by their knowledge, professionalism, and dedication. Their need for credible scientific evidence to inform their practice has never been more urgent. Despite the exponentially increasing number of publications since the start of the pandemic, questions remain unanswered, and more are created, than have been resolved by the increasing number of publications. A panel of leading journal editors was convened by the International Pharmaceutical Federation (FIP) Pharmacy Practice Research Special Interest Group to discuss the current status of COVID-19 related research, provide their recommendations, and identify focal points for pharmacy practice, social pharmacy, and education research moving forward. Key priorities identified spanned a wide range of topics, reflecting the need for good quality research to inform practice and education. The panel insisted that a foundation in theory and use of rigorous methods should continue forming the basis of inquiry and its resultant papers, regardless of topic area. From assessing the clinical and cost effectiveness of COVID-19 therapies and vaccines to assessing different models of pharmaceutical services and education delivery, these priorities will ensure that our practice is informed by the best quality scientific evidence at this very challenging time.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/152735